Cefprozil Anhydrous, (E)-
The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.
Masse moléculaire
389,4000 g/mol
LogP
-1,40
TPSA
158,00 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Structure 2D
Cite this structure
Embed this structure
SMILES
C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1
InChI
InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1
Molecular Formula
C18H19N3O5S
HBD / HBA
4 / 7
Liaisons Rotatives
5
Atomes Lourds
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The anhydrous E-isomer form of cefprozil is an oral second-generation cephalosporin used for mild to moderate upper and lower respiratory tract infections, otitis media, and skin infections. It contains a propenyl side chain that exists in E and Z geometric isomers. The clinical formulation is predominantly the E-isomer.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefprozil Anhydrous, (E)- is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL276568. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281006. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefprozil-anhydrous-e"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefprozil-anhydrous-e/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefprozil-anhydrous-e/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefprozil-anhydrous-e/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefprozil-anhydrous-e"></drugfyi-drug>